.png){kind=logo}
Overview
EXECUTIVE SUMMARY
The drug discovery industry faces a staggering 98% failure rate, signaling an urgent need for foundational innovation. Invented at The Rockefeller University, Chromovert® Technology dramatically optimizes the initial starting point of discovery, significantly upgrading the Probability of Technical and Regulatory Success (PTRS). The company is raising capital to scale this asset into a high-throughput “drug discovery engine” capable of continuously mining, verifying, and commercializing novel pipeline candidates. Having successfully validated Chromovert® across more than three dozen GPCRs, Secondcell Bio is positioned to launch the first drug discovery enterprise targeting all 400 GPCRs in parallel, unlocking significant competitive and clinical advantages.
Systemic Selectivity: Parallel discovery allows the team to “cherry-pick” only the most promising candidates meeting stringent benchmarks (potency, novelty, safety, market demand) before IND-enabling studies.
True Portfolio Diversification: Mechanistically designed to feed a continuous pipeline of diverse blockbusters rather than exposing venture capital to single clinical asset binary risks. Initial licensing deals will generate upfront cash, milestone payments, and royalties.
Biodefense & Dual-Use Potential
Dialogue with U.S. defense agencies to screen chemical warfare agents against the comprehensive GPCR panel, identifying immediate toxicity countermeasures from existing FDA therapeutics.
INVESTMENT HIGHLIGHTS
-
TRL9 Platform: Fully validated, debugged, and automated platform IP.
-
$150M+: In prior customer-funded R&D through a Rockefeller spin-out to mature the platform from concept to scale.
COMMERCIAL VALIDATION
-
Nestlé: Successfully discovered the first-known natural salt taste enhancers.
CAPITAL ROADMAP
-
Phase 1 ($15M-$20M+): Scale/industrialize core automation infrastructure, expand team, and execute on prime GPCR targets.
MANAGEMENT
Led by Kambiz Shekdar, PhD, a Rockefeller alumnus, molecular biologist, and primary inventor of the Chromovert® platform
Company Events
